MedTrace Logo

A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

NCT02232230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-01-09

No results posted yet for this study

Summary

Radiation in combination with Provenge based immunotherapy may improve outcomes seen on imaging as well as immunologic monitoring. This study will assess the effect of radiation therapy to augment anti-tumor responses from immune therapy with Provenge.

Conditions

  • Castrate Refractory Metastatic Prostate Cancer (mCRPC)

Interventions

DRUG

Provenge

Sponsors & Collaborators

  • Dendreon

    collaborator INDUSTRY

  • GenesisCare USA

    lead OTHER

Principal Investigators

  • Steven Finkelstein, MD · GenesisCare USA

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2018-06-05
Completion
2018-06-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02232230 on ClinicalTrials.gov